Scotland’s ProStrakan Group Gets Early UK Approval for Abstral

PharmaTimes -- Scotland-based speciality pharma ProStrakan Group has been boosted by an earlier-than-expected in the UK for the cancer drug Abstral a week after US regulators backed Sancuso, a patch for the prevention of chemotherapy-induced nausea and vomiting.
MORE ON THIS TOPIC